Market Overview

Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP Would Be Indicated for RA

Share:
Related ISIS
Benzinga's Top #PreMarket Gainers
ISIS Pharmaceuticals Cuts License Deal With Bayer AG
Can Isis Pharmaceuticals (ISIS) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape (Zacks)

Shares of Isis Pharma (NASDAQ: ISIS) have fallen nearly 3 percent Monday as the company announced it has halted development of its rheumatoid arthritis product as the latest study failed to demonstrate a benefit.

Needham analyst Chad Messer issued a research note earlier suggesting investors should use the dip in price to load up on shares. Messer pointed out he didn't consider the RA drug as a "serious consideration" for the company's ISIS-CRP. He believes the next catalyst for APOCIII monotherapy trial is later in August.

Needham maintains a Buy rating and $36 price target on shares of Isis Pharma.

Latest Ratings for ISIS

DateFirmActionFromTo
Mar 2015Deutsche BankMaintainsBuy
Mar 2015Brean CapitalDowngradesBuy
Mar 2015Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters